American Society of Clinical Oncology Now Recommends Evista or Tamoxifen to Reduce Risk in High-Risk Women
New guidelines from the American Society of Clinical Oncology (ASCO) now recommend both tamoxifen and Evista (chemical name: raloxifene) to reduce breast cancer risk in post-menopausal women at high risk.
A new study suggests that tamoxifen is successful at reducing breast cancer risk only in high-risk women whose breast density decreases by 10% or more during the first year or so of treatment.
Women at high risk who took tamoxifen and developed hormone-receptor-NEGATIVE breast cancer had the cancer diagnosed earlier compared to women who didn't take tamoxifen. (Tamoxifen doesn't reduce the risk of hormone-receptor-negative breast cancer.)